Drug recall · February 7, 2024
Rifampin Capsules USP 300mg recall
Why: Subpotent Drug and Failed Impurities/Degradation Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06
- Lots / codes
A200817 exp 1/2024
- Quantity
- 165,60 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.
- Initiated
- January 5, 2024 · Voluntary: Firm initiated
- Classified
- January 30, 2024
- Reported
- February 7, 2024
- Ended
- August 27, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rifampin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.